Citations

Clear

4564 citation(s) found for "Yu, Virginia".

S897 Impact of GLP-1 Agonist versus Opioid Use on Esophagogastroduodenoscopy (EGD) Outcomes: A Propensity-Matched Analysis of the U.S. Collaborative Network
Mohamed, Mouhand , Hamid, Osama , Awadalla, Mohanad, Guardiola, John, Mohamed, Mouhand F H , Beran, Azizullah , Elfert, Khaled , Bhavsar‐Burke, Indira

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S625-S626

10.14309/01.ajg.0001032956.79643.e5 Get It

S568 Repeated Liquid Nitrogen Spray Cryotherapy Treatment Results in Sustained Palliation for Some Patients With Esophageal Cancer
Eluri, Swathi , Sharma, Neil , Gordon, Stuart R. , Kachaamy, Toufic , Smallfield, George , Samarasena, Jason , Zolotarevsky, Eugene, Barber, Jeremy, Kothari, Shivangi , Chang, Kenneth J. , Benias, Petros C. , McKinley, Mathew, Juneja, Arjun K., Shaheen, Nicholas J. , Cotton, Cary C. , Kaul, Vivek , Trindade, Arvind J. , Willingham, Field F. , McKinley, Mathew

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S393-S394

10.14309/01.ajg.0001031640.11631.fe Get It

S560 GLP-1 Agonists Use Is Associated With Lower Use of PPI and Do Not Worsen Outcomes in Patients With GERD: A National Database Analysis
Narvaez, Sharon, Palacios-Argueta, Pedro, Ko, Donghyun , Chawla, Saurabh, Davisson, Laura , Nieto, Luis M., Palacios-Argueta, Pedro, Kim, Do Han , Vega, Kenneth J.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S388-S389

10.14309/01.ajg.0001031608.30677.6c Get It

Determinants of symptom presentation and resolution following concussions in high school sports
Boltz, Adrian J. , Lempke, Landon B. , Rao, Neel , Northam, Weston T. , Collins, Christy L. , Alexander, Andrew , Alexander, Andrew S , Chandran, Avinash S. , Alexander, Andrew S., DiPietro, Loretta

Mayo Clinic

Research in Sports Medicine | October 23, 2024 | Volume: 33 | Issue: 1 | Pages: 72-86

10.1080/15438627.2024.2414972 | PMID 39439229 Get It

Risk Stratification for Chronic Kidney Disease After Liver Transplant for Metabolic Dysfunction-associated Steatohepatitis (MASH) Cirrhosis: Results From the NailMASH Consortium
Satapathy, Sanjaya K. , Elwir, Saleh , Smith, Coleman I. , Jiang, Yu , Vanatta, Jason M. , Ha, Nghiem B. , Cheung, Amanda , Siddiqui, Mohammad Shadab , Rinella, Mary E. , Watt, Kymberly D., Sathapathy, Sanjaya , Rinella, Mary , Brandman, Danielle , Bhat, Mamatha , Patel, Pratik

Mayo Clinic

Transplantation | October 22, 2024 | Volume: 109 | Issue: 3 | Pages: 484-495

10.1097/tp.0000000000005236 | PMID 39434206 Get It

Background. Chronic kidney disease (CKD) is a well-recognized complication in patients undergoing liver transplantation (LT), particularly those with metabolic dysfunction-associated steatohepatitis (MASH), a leading cause of cirrhosis in the modern era. This study sought to refine risk stratification for CKD events post-LT in cirrhosis patients with MASH by leveraging baseline renal function at transplant. Methods. A total of 717 MASH cirrhosis patients who had LT (1997–2017) at 7 US centers (NailMASH Consortium) were analyzed. Patients were categorized by estimated glomerular filtration rate (eGFR) at transplant: low (LGFR, eGFR ≤30 mL/min/1.73 m²), medium (MGFR, eGFR >30–≤60 mL/min/1.73 m²), and high (HGFR, eGFR >60 mL/min/1.73 m²). Time-related eGFR intercepts, slopes, and assessments of advanced-stage CKD (aCKD) events, defined as 2 eGFR levels <30 mL/min/1.73 m² separated by ≥90 d, were examined. Results. Post-LT, LGFR group showed increased eGFR, whereas the HGFR group experienced a decline. The 3-mo mark was identified as a “reset point,” signifying a new reference level, beyond which a different rate of decline was observed. After 3 mo, mean eGFRs of the LGFR group approached MGFRs, whereas the mean eGFR of the HGFR group continued to decrease but remained higher than other groups during a 60-mo follow-up. LGFR patients had significantly higher aCKD probability than MGFR and HGFR groups. Subanalysis at 3 mo post-LT revealed more aCKD events in the LGFR group compared with MGFR and HGFR groups ( P < 0.0001). Conclusions. The study underscores renal impact of LT in MASH cirrhosis, indicating unique eGFR trajectories post-LT tied to baseline eGFR, with a reset point at 3 mo. Monitoring post-LT renal function, especially in those at aCKD risk, is crucial. Renal-sparing immunosuppression may help, regardless of baseline eGFR. Further studies are needed for interventions addressing renal dysfunction of patients with MASH post-LT.
Endovascular therapy versus medical management in isolated posterior cerebral artery acute ischemic stroke: A multinational multicenter propensity score-weighted study
Salim, Hamza , Pulli, Benjamin , Yedavalli, Vivek, Musmar, Basel , Adeeb, Nimer , Lakhani, Dhairya A. , Essibayi, Muhammed Amir , Naamani, Kareem El, Henninger, Nils , Sundararajan, Sri Hari , Khalife, Jane , Grewal, Inayat , Tan, Benjamin Yong‐Qiang , Regenhardt, Robert W. , Heit, Jeremy J , Rouchaud, Aymeric, Sheth, Sunil G. , Puri, Ajit S., Dyzmann, Christian , Barreau, Xavier, Filipe, João Pedro , Harker, Pablo, Abdalkader, Mohamad , Marotta, Thomas R. , Spears, Julian , Biswas, Arundhati , Clarençon, Frédéric , Varela, Ricardo , Baker, Amanda , Altschul, David , Gonzalez, Nestor R. , Möhlenbruch, Markus , Costalat, Vincent, Gory, Benjamin, Stracke, Christian Paul , Hecker, Constantin, Shaikh, Hamza, Liebeskind, David S. , Alexandre, Andrea , Tancredi, Illario, Faizy, Tobias D. , Kalsoum, Erwah , Lubicz, Boris , Patel, Aman B. , Guenego, Adrien, Investigators, for the MAD MT, Heit, Jeremy J. , Yedavalli, Vivek , Salim, Hamza , Lakhani, Dhairya , Scarcia, Luca , Regenhardt, Robert W , Fiehler, Jens , Alexandru Radu, Răzvan , Klein, Piers , Ota, Takahiro , Jabbour, Pascal , Nguyen, Thanh N , Gonzalez, Nestor R , Möhlenbruch, Markus A , Liebeskind, David S. , Alexandre, Andrea M , Faizy, Tobias D , Wintermark, Max , Heit, Jeremy J , Altschul, David J , Musmar, Basel , Essibayi, Muhammed Amir , Yedavalli, Vivek S , Henninger, Nils , Tan, Benjamin Yq , Pulli, Benjamin , Varela, Ricardo , Naamani, Kareem El , Kühn, Anna Luisa , Ghozy, Sherief , Cancelliere, Nicole M , Bernstock, Joshua D. , Rouchaud, Aymeric , Fiehler, Jens , Sheth, Sunil, Puri, Ajit S , Colasurdo, Marco , Barreau, Xavier , Renieri, Leonardo , Harker, Pablo , Radu, Răzvan Alexandru , Klein, Piers , Mowla, Ashkan , Jabbour, Pascal , Siegler, James E. , Nguyen, Thanh N. , Costalat, Vincent , Gory, Benjamin , Aziz‐Sultan, Mohammad Ali , Hecker, Constantin , Griessenauer, Christoph J. , Pedicelli, Alessandro , Tancredi, Illario , Mendes Pereira, Vitor , Guenego, Adrien , Dmytriw, Adam A. , Investigators, for the MAD MT

Mayo Clinic

European Stroke Journal | October 21, 2024 | Volume: 10 | Issue: 2 | Pages: 387-396

10.1177/23969873241291465 | PMID 39431327 Get It

Abstract Background: Despite the proven effectiveness of endovascular therapy (EVT) in acute ischemic strokes (AIS) involving anterior circulation large vessel occlusions, isolated posterior cerebral artery (PCA) occlusions (iPCAo) remain underexplored in clinical trials. This study investigates the comparative effectiveness and safety of EVT against medical management (MM) in patients with iPCAo. Methods: This multinational, multicenter propensity score-weighted study analyzed data from the Multicenter Analysis of primary Distal medium vessel occlusions: effect of Mechanical Thrombectomy (MAD-MT) registry, involving 37 centers across North America, Asia, and Europe. We included iPCAo patients treated with either EVT or MM. The primary outcome was the modified Rankin Scale (mRS) at 90 days, with secondary outcomes including functional independence, mortality, and safety profiles such as hemorrhagic complications. Results: A total of 177 patients were analyzed (88 MM and 89 EVT). EVT showed a statistically significant improvement in 90-day mRS scores (OR = 0.55, 95% CI = 0.30–1.00, p = 0.048), functional independence (OR = 2.52, 95% CI = 1.02–6.20, p = 0.045), and a reduction in 90-day mortality (OR = 0.12, 95% CI = 0.03–0.54, p = 0.006) compared to MM. Hemorrhagic complications were not significantly different between the groups. Conclusion: EVT for iPCAo is associated with better neurological outcomes and lower mortality compared to MM, without an increased risk of hemorrhagic complications. Nevertheless, these results should be interpreted with caution due to the study’s observational design. The findings are hypothesis-generating and highlight the need for future randomized controlled trials to confirm these observations and establish definitive treatment guidelines for this patient population.
Development of a Uniform Apheresis Case Report Form for Standardized Collection of Apheresis Data
Johnson, Andrew D., Szczepiorkowski, Zbigniew M. , Karam, Oliver , Nellis, Marianne E. , Schwartz, Joseph, Wu, Yanyun , Armendariz, Tomas , Burgstaler, Edwin A. , Collins, Laura , Geile, Kira, Pavenski, Katerina , Sanchez, Amber P. , Witt, Volker, Muthusamy, Amutha, Ramesh, Vidhyalakshmi , Thao, Mai See , Chlebeck, Therese M., Zantek, Nicole D. , Karam, Oliver , Armendariz, Tomas , Burgstaler, Edwin, Zantek, Nicole D , Balogun, Rasheed A. , Schneiderman, Jennifer , Winters, Jeffrey L. , Pavenski, Katerina , Pederson, Thomas

Mayo Clinic

Journal of Clinical Apheresis | October 18, 2024 | Volume: 39 | Issue: 5 | Pages: No page available

10.1002/jca.22146 | PMID 39420527 Get It

ABSTRACTApheresis is performed worldwide for an increasing number of indications. The development of common data elements (CDE) for apheresis related areas may facilitate conduct of new research, enhance quality initiatives including benchmarking, and improve patient care. This report describes the systematic development of the Uniform Apheresis Case Report Form (UACRF) as part of the Apheresis in the United States (ApheresUS) program. A consensus panel of 17 diverse experts in apheresis, related specialties, and electronic case report form (eCRF), and database development was assembled. The panel met via online conferencing from November 17, 2020 to December 1, 2021. A draft document was posted online for public comment from October 11, 2021 to November 10, 2021. Feedback was collected using an online survey tool. The consensus panel revised the UACRF. This version was converted to an eCRF with additional changes made to improve usability in this format. The final version of the UACRF was created on August 24, 2023. The UACRF contains 16 modules: procedure and subject eligibility, patient demographics, general procedure information, laboratory parameters, vascular access, common procedure elements, eight procedure specific modules (mononuclear cell collection and seven therapeutic modalities), outcomes, and site information. A total of 137 data elements were created, including 57 with one or more subelements. The UACRF is the first systematic attempt to develop CDE for therapeutic apheresis and white blood cell collections. Further validation of the UACRF is necessary to confirm the tool's ability to collect the relevant data elements and determine the usability of the form.
P14.05.A A PROSPECTIVE, MULTICENTER TRIAL OF FOCUSED ULTRASOUND FOR BLOOD-BRAIN BARRIER DISRUPTION FOR LIQUID BIOPSY IN GLIOBLASTOMA (LIBERATE)
Ozair, Ahmad , Sahgal, Arjun , Groot, John Frederick De, Hibert, Matthew , Zhu, James , Achrol, Achal S. , Shah, Bhavya , Patel, Toral , Rincon-Toroella, Jordina, Sporrer, Justin, Hilliard, Justin D. , Bezchlibnyk, Yarema , Rezai, Ali R. , Lipsman, Nir , Woodworth, Graeme F., Ozair, Ahmad , Ahluwalia, Manmeet S. , Burns, Terry C. , McDermott, Michael , Mogilner, Alon Y. , Mishra, Mark V. , Everson, Richard G. , Weinberg, Jeffrey S. , Cifarelli, Christopher P.

Mayo Clinic

Neuro-Oncology | October 17, 2024 | Volume: 26 | Issue: Supplement_5 | Pages: v77-v78

10.1093/neuonc/noae144.256 Get It

Abstract BACKGROUND Liquid biopsy in glioblastoma (GBM) is hindered by a lack of requisite circulating tumor (ct) and cell-free (cf) DNA levels in blood due to the blood-brain barrier (BBB). This limits the identification of blood-based tumor biomarkers along with the development and use of biomarker-driven systemic therapies. Real-time image-guided low intensity focused ultrasound (LIFU) combined with intravenously administered microbubble oscillators, leads to non-invasive disruption of the BBB. This trial aims to evaluate the utility of LIFU for boosting blood ctDNA and cfDNA for enhanced liquid biopsy in GBM patients. MATERIAL AND METHODS LIBERATE is an ongoing, prospective, multi-center, self-controlled, pivotal trial evaluating safety and technical efficacy of LIFU-based BBB disruption for increasing blood ctDNA and cfDNA levels in adults, aged 18-80 years with GBM. Patients with suspected GBM planned for tumor biopsy or resection at ten centers in the US are being enrolled. Patients with multifocal tumors or tumors arising from deep midline, thalamus, cerebellum, or brainstem are excluded. Patients are administered IV microbubbles for enhanced sonication effects, after which MR-guided BBB disruption using a 220 kHz LIFU device is performed with real-time acoustic feedback control for effective microbubble activation. Before and after procedure, phlebotomy and MRI brain are performed to evaluate outcomes. Primary study endpoint is defined, per subject, as ratio between their cfDNA level in blood 1-hour post-LIFU procedure compared to cfDNA level in blood pre-procedure. Primary study hypothesis is that BBB disruption with LIFU leads to a ≥2-fold rise in blood cfDNA. The secondary hypothesis is that there exists ≥75% agreement between biomarker pattern in blood cfDNA sample obtained 1-hour post-LIFU and the biomarker pattern in tumor tissue obtained later. The trial has been powered to evaluate both primary and secondary hypotheses. Based on an assumed true agreement rate of 91% and a one-sided alpha of 0.025, an exact test for binomial proportions provides a sample of N = 50 with 84% power for the secondary hypothesis. Exploratory endpoints include (1) sensitivity of detection of known specific somatic mutations in ctDNA from blood samples collected before and after LIFU, (2) estimation of ctDNA levels post-LIFU in samples collected at 30 minutes, 1 hour, 2 hour, and 3 hour to determine the time of greatest yield, (3) correlation of MRI parameters related to grading of BBB disruption and ctDNA-based biomarkers from post-LIFU blood samples. RESULTS Patient enrollment commenced in 2022, and 22 patients have been recruited by 05/2024. CONCLUSION Findings from this trial will be critical to liquid biopsy in GBM (Clinical trial information: NCT05383872).
Incidence of revision surgery and patient-reported outcomes within 5 years of the index procedure for grade 1 spondylolisthesis: an analysis from the Quality Outcomes Database spondylolisthesis data
Birlingmair, Jacob, Djurasovic, Mladen, Mummaneni, Praveen V. , Asher, Anthony L. , Bisson, Erica F. , Bydon, Mohamad , Chan, Andrew K. , Chou, Dean , Coric, Domagoj , Foley, Kevin T. , Fu, Kai-Ming, Haid, Regis W., Knightly, John J. , Le, Vivian , Potts, Eric A. , Shaffrey, Christopher I. , Shaffrey, Mark E., Slotkin, Jonathan R., Virk, Michael S. , Wang, Michael Y. , Glassman, Steven D. , Carreon, Leah Y. , Park, Paul

Mayo Clinic

Journal of Neurosurgery: Spine | October 12, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-6

10.3171/2024.6.spine24488 | PMID 39393106 Get It

OBJECTIVE Some patients treated surgically for grade 1 spondylolisthesis require revision surgery. Outcomes after revision surgery are not well studied. The objective of this study was to determine how revision surgery impacts patient-reported outcomes (PROs) in patients undergoing decompression only or decompression and fusion (D+F) for grade 1 spondylolisthesis within 5 years of the index surgery. METHODS Patients in the 12 highest Quality Outcomes Database (QOD) enrolling sites with a diagnosis of grade 1 spondylolisthesis were identified and the incidence of revision surgery between the decompression-only and D+F patients were compared. PROs were compared between cohorts requiring revision surgery versus a single index procedure. RESULTS Of 608 patients enrolled, 409 had complete 5-year data available for this study. Eleven (13.3%) of 83 patients underwent revision in the decompression-only group as well as 32 (9.8%) of 326 in the D+F group. For the entire cohort, patients requiring revision had significantly worse PROs at 5 years: Oswestry Disability Index (ODI) 27.4 versus 19.4, p = 0.008; numeric rating scale for back pain (NRS-BP) 4.1 versus 3.0, p = 0.013; and NRS for leg pain (NRS-LP) 3.4 versus 2.1, p = 0.029. In the decompression-only group, the change in 5-year PROs was not impacted by revision status: ODI 31.9 versus 24.2, p = 0.287; NRS-BP 1.9 versus 2.9, p = 0.325; and NRS-LP 6.2 versus 3.7, p = 0.011. In the D+F group, the change in 5-year PROs was diminished if patients required revision: ODI 19.1 versus 29.1, p = 0.001; NRS-BP 3.0 versus 4.0, p = 0.170; and NRS-LP 2.3 versus 4.6, p = 0.001. CONCLUSIONS The most common reasons for reoperation within 5 years in the decompression-only group were repeat decompression and instability, whereas in the D+F group the most common reason was adjacent-segment disease. The need for revision resulted in modestly diminished benefit compared with patients with no revisions. These differences were greater in the fusion cohort compared with the decompression-only cohort. The mean PRO improvement still far exceeded minimal clinically important difference thresholds for all measures for patients who underwent a revision surgery.
Predicting Futile Recanalization After Endovascular Thrombectomy for Patients With Stroke With Large Cores: The SNAP Score
Matsukawa, Hidetoshi , Uchida, Kazutaka , Maier, Ilko , Jabbour, Pascal , Kim, Joon‐Tae , Wolfe, Stacey Q , Rai, Ansaar , Starke, Robert M. , Psychogios, Marios‐Nikos, Samaniego, Edgar A. , Grossberg, Jonathan A , Tanweer, Omar , Mascitelli, Justin, Polifka, Adam , Crosa, Roberto , Park, Min S. , Brinjikji, Waleed , Williamson, Richard , Navía, Pedro , Kan, Peter , Chowdhry, Shakeel , Ezzeldin, Mohamad , Spiotta, Alejandro M , Collaborators, for the Stroke Thrombectomy and Aneurysm Registry (STAR), Crosa, Roberto , Samaniego, Edgar A , Wolfe, Stacey Quintero , Matsukawa, Hidetoshi , Navia, Pedro , Chen, Huanwen , Elawady, Sameh Samir , Cunningham, Conor M. , Sowlat, Mohammad‐Mahdi , Jabbour, Pascal , Arthur, Adam Stephen , Yoshimura, Shinichi , Cuellar, Hugo, Alawieh, Ali , Romano, Daniele G., Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Matouk, Charles , Levitt, Michael R. , Moss, Mark, Leacy, Reade De , Collaborators, for the Stroke Thrombectomy and Aneurysm Registry (STAR)

Mayo Clinic

Neurosurgery | October 11, 2024 | Volume: 96 | Issue: 5 | Pages: 1080-1088

10.1227/neu.0000000000003220 | PMID 39471074 Get It

BACKGROUND AND OBJECTIVES: We aimed to develop and validate a prediction score for futile recanalization (FR) for large vessel occlusion (LVO) presenting low Alberta Stroke Program Early Computed Tomography Score (ASPECTS) for patients who underwent endovascular thrombectomy (EVT). METHODS: Patients with anterior circulation LVO with low ASPECTS (<6) who underwent successful EVT (modified treatment in cerebral ischemia score ≥2b) from Stroke Thrombectomy and Aneurysm Registry were retrospectively analyzed. FR was defined as 90-day modified Rankin Scale (mRS) scores ≥4 despite successful EVT. Multivariable logistic regression was used to identify independent predictors of FR, and they were used to create a clinical score. The performance of the score was assessed by receiver operating characteristic curve analyses. RESULTS: Of 219 patients, 170 and 49 patients were randomly assigned to the training and validation cohort, respectively. Independent predictors of FR identified in the training cohort were used to construct the SNAP score: site of occlusion (middle cerebral artery = 0, internal carotid artery = 1), National Institutes of Health Stroke Scale score at admission (≤10 = 0, 10 to 19 = 1, ≥20 = 2), age (<75 = 0, ≥75 = 2), and prestroke mRS score (0-3). Receiver operating characteristic curve analyses of the SNAP score in the training and validation cohorts showed areas under the curve of 0.79 (95% CI 0.72-0.86) and 0.79 (95% CI 0.65-0.92) for predicting FR, respectively. A SNAP score ≥5 had a positive predictive value of 92.1% [95% CI 78.8%-97.3%] for FR. CONCLUSION: The SNAP score may be useful in predicting FR after EVT in low-ASPECTS patients with LVO. It can provide patients, family members, and physicians with reliable outcome expectations among patients with acute ischemic stroke with large infarcts.